Introduction
============

Breast cancer is the most common cancer in women worldwide.[@b1-ott-11-5293] Based on the expression profiles, breast cancer is divided into Luminal A, Luminal B, Her2 high expression and Basal-like subtypes, all of which have their specific tumor biological characteristics.[@b2-ott-11-5293] Although endocrine therapy, Her2-targeted, CDK4/6 inhibitor and chemotherapy have greatly improved the survival of breast cancer patients, the drug resistance and recurrence are still the main obstacles in clinical treatment.[@b3-ott-11-5293] Therefore, it is necessary to find novel targets, markers or methods for breast cancer treatment.

Neuropilin 1 (NRP-1) has been proven to be highly expressed in various tumors, such as lung, gastric and breast cancers.[@b4-ott-11-5293]--[@b6-ott-11-5293] A previous study has indicated that NRP-1 is an associated molecule in the blood, which distinguishes poor prognosis of breast cancer.[@b7-ott-11-5293] NRP-1 is an angiogenic co-receptor of VEGF-A, and VEGF-A/NRP-1 axis could promote breast cancer progression via enhancement of epithelial--mesenchymal transition (EMT) and activation of NF-κB and β-catenin signaling.[@b8-ott-11-5293] Notably, a previous research has reported that peptides inhibiting the binding of VEGF-A/NRP-1 could inhibit breast cancer progression,[@b9-ott-11-5293] and two groups have demonstrated that a monoclonal antibody targeting neuropilin-1 or a neuropilin-1 antagonist could exert anticancer effects in breast cancer via in vitro and in vivo experiments.[@b10-ott-11-5293],[@b11-ott-11-5293] Our studies have previously shown that RNA interference-mediated NRP-1 silencing could inhibit breast cancer cell proliferation and promote cell apoptosis, and VEGF-A/NRP-1 pathway could confer cancer stemness via activating Wnt/β-Catenin axis in breast cancer cells.[@b12-ott-11-5293],[@b13-ott-11-5293] However, the mechanisms by which NRP-1 is regulated in breast cancer cells are still not clear.

miRNAs are a kind of noncoding RNA, which could inhibit the expression of transcripts by directly binding to transcripts and thus promoting their degradation or inhibiting their translation.[@b14-ott-11-5293] Various studies have indicated that miRNAs hold critical roles in tumor progression, for example, Muhammad et al[@b15-ott-11-5293] demonstrated that anti-miR-203 suppresses breast cancer growth and stemness by targeting SOCS3 and Hu et al[@b16-ott-11-5293] showed that miR-125b inhibits acute myeloid leukemia cell differentiation by directly targeting Fes. A previous study has indicated that miR-376a could regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells.[@b17-ott-11-5293] miR-376a serves as a potential diagnostic and prognostic marker in ovarian cancer patients[@b18-ott-11-5293] and human gliomas.[@b19-ott-11-5293] It also acts as a tumor suppressor in non-small-cell lung cancer[@b20-ott-11-5293] and giant cell tumor of bone.[@b21-ott-11-5293] However, there is no evidence reporting the roles and related mechanisms in breast cancer progression.

In this study, we first explored the correlation between miR-376a expression and the overall survival (OS) of breast cancer patients, and we found that miR-376a expression was positively correlated with the OS of breast cancer patients, which indicates the inhibitory role of miR-376a in breast cancer. Furthermore, cell viability, cell apoptosis, migration and invasion assays were performed to prove our speculation. Finally, our results demonstrate that miR-376a could directly target to NRP-1 and inactivate the downstream axis Wnt/β-catenin. Thus, we concluded that miR-376a acts as a tumor suppressor via targeting NRP-1 in breast cancer.

Materials and methods
=====================

Kaplan--Meier (KM) plotter analysis
-----------------------------------

KM plotter analysis was done to evaluate the correlation between miR-376a expression and the OS of breast cancer patients following the previous study.[@b22-ott-11-5293] Breast cancer METABRIC and GSE19783 datasets were used for this analysis, which include 1,262 and 101 breast cancer patients, respectively, and the cutoff was autoselected.

Cell cultures and reagents
--------------------------

Breast cancer cell lines MCF-7, MDA-MB-453 and MDA-MB-231 and breast epithelial cells MCF-10A were purchased from the China Academia Sinica Cell Repository (Shanghai, China). MCF-10A, MCF-7 and MDA-MB-453 cells were cultured in DMEM (Thermo Fisher Scientific, Waltham, MA, USA), and MDA-MB-231 cells were maintained in L-15 medium (Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS; Thermo Fisher Scientific), 80 U/mL penicillin and 0.08 mg/mL streptomycin at 37°C under humidified atmosphere with 5% CO~2~. Wnt/β-catenin agonist, SKL2001 (S8320), was purchased from Selleck.cn (Houston, TX, USA).

Lentivirus package and stable infection cell line construction
--------------------------------------------------------------

The NRP-1 overexpression lentivirus vector was constructed in our previous study and referred to as LV-NRP-1.[@b12-ott-11-5293] We thank RiboBio Inc. (Guangzhou, China) for constructing miR-376a overexpression lentivirus vector, LV-miR-376a and miR-control lentivirus (control). For constructing miR-376a stable overexpression cells, MDA-MB-453 and MDA-MB-231 cells were infected with LV-miR-376a virus or control virus in the presence of 2 µg/mL of polybrene. After 48 hours, the cells were selected with 1.5 µg/mL of puromycin (Sigma-Aldrich Co., St Louis, MO, USA) for 3 weeks. Furthermore, quantitative real-time PCR (qRT-PCR) was used to examine the infection efficiency of miR-376a in cells.

Cell viability assay
--------------------

MDA-MB-453 and MDA-MB-231 cells were seeded in 96-well plates at 4.0×10^3^ cells/well with LV-NRP-1 infection or not. After 24 hours, 48 hours and 72 hours, cell viability was detected using CCK8 assay (MedChemExpress, Cat No: HY-K0301) according to the manufacturer's protocols.

Cell apoptosis assay
--------------------

MDA-MB-453 and MDA-MB-231 cells with miR-376a stable overexpression were infected with LV-NRP-1 and washed with cold PBS, and then resuspended in the binding buffer containing Annexin V--fluorescein isothiocyanate (FITC) and propidium iodide (PI; Beyotime, Beijing, China) for 15 minutes in the dark at room temperature. Cell apoptosis was then detected by the FACS flow cytometry (BD Biosciences, San Jose, CA, USA).

Cell migration and invasion assay
---------------------------------

The detailed procedure is mentioned in the previous study.[@b23-ott-11-5293] In this study, the measure time of migration and invasion was 24 and 48 hours, respectively.

qRT-PCR assay
-------------

Total RNA was extracted using TransZol Up (TransGen Biotech, Beijing, China) following the manufacturer's protocols. cDNA synthesis and qRT-PCR assay for miR-376a were performed using Hairpin-itTM Real-Time PCR miRNAs kit (GenePharma, Shanghai, China). cDNA synthesis for mRNA was performed using EasyScript First-Strand cDNA Synthesis SuperMix (TransGen Biotech), and Custom Real-Time PCR Gene Detection Assay (GenePharma) was used to analyze mRNA expression. All qRT-PCR reactions were performed on an ABI Prism 7500 Detection System (Thermo Fisher Scientific). GAPDH was served as an internal control. The relative gene expression was analyzed using the 2^−ΔΔct^ method.

Western blot
------------

The detailed procedure is mentioned in our previous study.[@b12-ott-11-5293] The primary antibodies against NRP-1 (ab81321), E-cadherin (ab1416), Vimentin (ab8978), Wnt3a (ab28472), β-catenin (ab32572), anti-cleaved caspase 3 (ab32042), anti-cleaved PARP (ab32064), Caspase 3 (ab13847), PARP (ab74290) and β-actin (ab8226) were purchased from Abcam (Cambridge, UK). The secondary antibodies IgG(H+L) (HRP-labeled Goat Anti-Mouse IgG(H+L)) (A0216) and IgG(H+L) (HRP-labeled Goat Anti-Rabbit IgG(H+L)) (A0208) were purchased from Beyotime. Specific signals were detected using ECL chemiluminescence detection kit (Thermo Fisher Scientific) on Tanon 6200 (Tanon, Shanghai, China). β-Actin was used as an internal control.

Luciferase reporter assay pMIR-Reporter (Promega Corporation, Fitchburg, WI, USA) was used to introduce the fragments of NRP-1--3′-UTR containing the wild-type (wt) and mutant binding sites (mut) for miR-376a, named as Luc-NRP-1-wt and Luc-NRP-1-mut, respectively. Luc-NRP-1-wt or Luc-NRP-1-mut with β-gal plasmid was transfected into breast cancer cells with miR-376a overexpression using Lip2000 (Thermo Fisher Scientific) according to the standard procedure. After 72 hours, cells were collected and used for luciferase activity analysis using ONE-Glo™+Tox Luciferase Reporter and Cell Viability Assay kit (E7110) and VivoGlo Luciferin-β-gal Substrate kit (P1061). The luciferase activity was normalized with the β-gal activity.

RNA immunoprecipitation (RIP) of Ago2
-------------------------------------

The detailed procedure is mentioned in the previous study.[@b24-ott-11-5293] Briefly, MCF-7 and MDA-MB-231 cells transfected with Luc-NRP-1-wt or Luc-NRP-1-mut were lysed with 25 mM Tris-HCl buffer (pH 7.5) and 100 U/mL RNase inhibitor (Sigma-Aldrich Co.), and then incubated with protein-A sepharose beads pre-coated with 3 µg anti-Ago2 antibody or control rabbit IgG for 1.5 hours at 4°C. The RNA--protein complexes were pulled down by protein A/G agarose beads, and RNA was extracted with TransZol Up, and miR-376a level was measured by qRT-PCR.

Statistical analysis
--------------------

All data were presented as mean±SD. Datasets with only two groups were analyzed using a Student's *t*-test. The differences between the groups were analyzed using one-way ANOVA with the Tukey--Kramer post-test, and *P*\<0.05 was considered significant.

Results
=======

miR-376a is downregulated and predicted to target NRP-1 in breast cancer cells
------------------------------------------------------------------------------

Since other and our groups had previously reported the promotive effects of NRP-1 on breast cancer progression,[@b7-ott-11-5293],[@b8-ott-11-5293],[@b12-ott-11-5293],[@b13-ott-11-5293] here we sought to reveal the mechanisms by which NRP-1 was regulated in breast cancer cells. [miRNA.org](http://miRNA.org) (<http://34.236.212.39/microrna/getMrna.do?gene=8829&utr=20945&organism=9606>) was used to predict the potential miRNAs that could target NRP-1. miR-376a attracted our attention based on the fact that miR-376a held two potential binding sites on NRP-1 3′-UTR ([Figure 1A](#f1-ott-11-5293){ref-type="fig"}). KM plotter analysis based on METABRIC and GSE19783 datasets showed that miR-376a expression was positively correlated with the OS of breast cancer patients ([Figure 1B and C](#f1-ott-11-5293){ref-type="fig"}). qRT-PCR was further used to detect the miR-376a level in breast cancer and breast epithelial cells, and results indicated that the miR-376a level was significantly downregulated in breast cancer cells ([Figure 1D](#f1-ott-11-5293){ref-type="fig"}), which is opposite to the expression pattern of NRP-1 in breast cancer. Notably, miR-376a expression was negatively correlated with the metastatic ability of breast cancer cells (MCF-7, low metastatic ability; MDA-MB-453, median metastatic ability; and MDA-MB-231, high metastatic ability). Here, MDA-MB-453 and MDA-MB-231 cells were chosen for the following study.

miR-376a could directly bind to NRP-1 and inactivate the downstream Wnt/β-catenin axis in breast cancer cells
-------------------------------------------------------------------------------------------------------------

Then, we continue investigating whether miR-376a could indeed target NRP-1 in breast cancer cells. qRT-PCR and Western blot analyses showed that breast cancer cells with miR-376a stable overexpression exhibited relative lower expression level of NRP-1 than that in control cells without miR-376a overexpression ([Figure 2A and B](#f2-ott-11-5293){ref-type="fig"}). The infection efficiency of LV-miR-376a was confirmed by qRT-PCR assay ([Figure 2C](#f2-ott-11-5293){ref-type="fig"}). Further luciferase reporter assay indicated that miR-376a could decrease the activity of Luc-NRP-1-wt but had no effect on the Luc-NRP-1-mut activity ([Figure 2D and E](#f2-ott-11-5293){ref-type="fig"}). To confirm the direct interaction between miR-376a and NRP-1 at endogenous levels, we performed RIP analysis to pull down endogenous miRNAs associated with Ago2 in Luc-NRP-1-wt-overexpressed breast cancer cells. The precipitated miRNAs were subjected to qRT-PCR analysis, and results showed that miR-376a was enriched in RNAs retrieved from Luc-NRP-1-wt-overexpressed cells compared with Luc-NRP-1-mut-overexpressed or control cells ([Figure 2F](#f2-ott-11-5293){ref-type="fig"}); these results supported that NRP-1 was the bona fide target of miR-376a in breast cancer cells. As we had demonstrated that overexpression of NRP-1 could activate the downstream Wnt/β-catenin signaling, we speculated that miR-376a could inactivate this signaling. As expected, miR-376a overexpression significantly decreased Wnt3a and β-catenin expression in breast cancer cells ([Figure 2G](#f2-ott-11-5293){ref-type="fig"}). Our results suggested that miR-376a could target NRP-1 and inactivate the downstream signaling in breast cancer cells.

miR-376a overexpression inhibits breast cancer cell proliferation and promotes cell apoptosis
---------------------------------------------------------------------------------------------

Based on the correlation between miR-376a and the OS of breast cancer patients, we assumed that miR-376a held inhibitory effects on breast cancer progression. Cell viability assay indicated that miR-376a overexpression inhibited breast cancer cell proliferation ([Figure 3A and B](#f3-ott-11-5293){ref-type="fig"}). Further, cell apoptosis analysis showed that overexpression of miR-376a significantly potentiated cell apoptotic rate in breast cancer cells ([Figure 3C and D](#f3-ott-11-5293){ref-type="fig"}). Additionally, the expression of apoptotic executors (cleaved caspase3 and cleaved PARP) was examined by Western blot, and consistent results were obtained with an increase in cleaved caspase3 and cleaved PARP expression ([Figure 3E](#f3-ott-11-5293){ref-type="fig"}).

miR-376a overexpression suppresses breast cancer cell migration, invasion and EMT process
-----------------------------------------------------------------------------------------

Since miR-376a expression was negatively correlated with the metastatic ability of breast cancer cells, we further explored whether miR-376a could suppress breast cancer migration and invasion. As shown in [Figure 4A](#f4-ott-11-5293){ref-type="fig"}, MDA-MB-453 and MDA-MB-231 cells with miR-376a stable overexpression exhibited relative lower migration ability compared with control. Consistent results were acquired in the examination of invasion ability ([Figure 4B](#f4-ott-11-5293){ref-type="fig"}). As EMT process plays a critical role in tumor metastasis, the effects of miR-376a on breast cancer EMT process were detected. We found that miR-376a overexpression decreased the mesenchymal marker (Vimentin) expression, while it increased the epithelial marker (E-cadherin) expression ([Figure 4C](#f4-ott-11-5293){ref-type="fig"}). Thus, our results demonstrate that miR-376a holds inhibitory effects on breast cancer cell progression.

Overexpression of NRP-1 or inhibition of wnt/β-catenin signaling rescues the inhibitory effects of miR-376a on breast cancer cell progression
---------------------------------------------------------------------------------------------------------------------------------------------

Finally, we further investigated whether the inhibitory effects of miR-376a were dependent on NRP-1 expression and downstream Wnt/β-catenin signaling. First, cell viability analysis showed that infection with LV-NRP-1 or treatment with Wnt/β-catenin agonist, SKL2001, in miR-376a over-expression cells attenuated the inhibition of miR-376a on cell viability ([Figure 5A and B](#f5-ott-11-5293){ref-type="fig"}). Furthermore, cell migration assay indicated that overexpression of NRP-1 or SKL2001 treatment rescued miR-376a overexpression-mediated inhibition on breast cancer cell migration and EMT process ([Figure 5C and D](#f5-ott-11-5293){ref-type="fig"}). Consistent results were obtained in cell apoptosis assay ([Figure 5E and F](#f5-ott-11-5293){ref-type="fig"}). Therefore, these results suggest that miR-376a overexpression-mediated inhibition on breast cancer cell progression is partly through NRP-1/Wnt/β-catenin axis.

Discussion
==========

Here, miR-376a inhibitory roles and related mechanisms were first revealed in breast cancer cell progression, which was clarified by the following experiments. First, miR-376a expression was positively correlated with the OS of breast cancer patients, and overexpression of miR-376a inhibited breast cancer cell proliferation, migration, invasion and promoted cell apoptosis. Second, we confirmed that miR-376a could directly bind to NRP-1 and inactivate the downstream Wnt/β-catenin signaling. Finally, we indicated that NRP-1 overexpression or treatment with Wnt/β-catenin agonist, SKL2001, could rescue the inhibitory effects of miR-376a overexpression on breast cancer cell progression. To the best of our knowledge, this is the first study revealing the roles and related mechanisms of miR-376a in breast cancer.

Other previous studies and this study had indicated the promotive roles of NRP-1 in breast cancer;[@b7-ott-11-5293],[@b8-ott-11-5293],[@b12-ott-11-5293],[@b13-ott-11-5293] however, the mechanisms by which NRP-1 was regulated were unclear. Here, miR-376a was chosen for exploration because it had two potential binding sites on NRP-1 3′-UTR. Notably, another member of miR-376 cluster, miR-376b, was also predicted to hold two potential binding sites on NRP-1 3′-UTR, and miR-376b expression was also positively correlated with the OS of breast cancer patients (data not shown). We are not sure whether miR-376b holds similar effects to miR-376a, and whether miR-376a and miR-376b could exert additive effects on breast cancer progression, which should be evaluated in the future works. Based on the critical roles of NRP-1 in breast cancer progression, potential methods targeting NRP-1 were elucidated in several groups;[@b10-ott-11-5293],[@b11-ott-11-5293] however, the clinical application is still not shown, which might remind us that the mechanisms by which NRP-1 is regulated or NRP-1 functioned still need much more elucidations. In this work, we showed that miR-376a could regulate NRP-1 expression at the transcriptional level, and other miRNAs or other regulatory mechanisms by which NRP-1 was regulated at the translational level should be identified.

Importantly, we must admit that the phenomena and mechanisms identified by us were not confirmed by in vivo experiments. Since NRP-1 overexpression or Wnt/β-catenin agonist, SKL2001, just could rescue but not reverse the inhibition of miR-376a overexpression on breast cancer cell progression, and one miRNA could target several transcripts, while one transcript could be targeted by several miRNAs.[@b14-ott-11-5293] For example, miR-376a could suppress the proliferation and invasion of non-small-cell lung cancer by targeting c-Myc20 and act as a tumor suppressor by targeting COA1 and PDIA6 in the giant cell tumor of bone.[@b25-ott-11-5293] miRNA-124-3 p/NRP-1 axis plays an important role in mediating glioblastoma growth and angiogenesis.[@b26-ott-11-5293] Therefore, other transcripts, such as c-Myc, COA1 and PDIA6, might involve in miR-376a-mediated inhibition on breast cancer cell progression, and NRP-1 could be regulated by other miRNAs, such as miR-124-3 p, in breast cancer.

Altogether, based on the in vitro experiments in this study, our work reveals an unpredicted layer of NRP-1 regulation and puts the activation of miR-376a as a potential novel therapeutic strategy to specifically inhibit breast cancer progression ([Figure 6](#f6-ott-11-5293){ref-type="fig"}).
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![miR-376a is downregulated and predicted to target NRP-1 in breast cancer cells.\
**Notes:** (**A**) [miRNA.org](http://miRNA.org) software predicted that miR-376a held two potential binding sites on NRP-1 3′-UTR. (**B** and **C**) KM plotter analysis indicated that miR-376a expression was positively correlated with the OS of breast cancer patients based on METABRIC and GSE19783 datasets. (**D**) miR-376a level was examined in breast cancer (MCF-7, MDA-MB-453 and MDA-MB-231) and breast epithelial (MCF-10A) cells. Data were presented as mean ± SD; \*\**P*\<0.01 vs NC or control.\
**Abbreviations:** KM, Kaplan--Meier; NRP-1, neuropilin-1; OS, overall survival; NC, negative control.](ott-11-5293Fig1){#f1-ott-11-5293}

![miR-376a could directly bind to NRP-1 and inactivate the downstream Wnt/β-catenin axis in breast cancer cells.\
**Notes:** (**A** and **B**) NRP-1 mRNA and protein expression was decreased in MDA-MB-453 and MDA-MB-231 cells with LV-miR-376a infection. (**C**) The infection efficiency of LV-miR-376a was confirmed by qRT-PCR analysis. (**D** and **E**) The luciferase activity of Luc-NRP-mut and Luc-NRP-1-wt was detected in cells depicted in (**A**). (**F**) miR-376a level was determined in RNA after being pulled down with anti-Ago2 from breast cancer cells with Luc-NRP-mut or Luc-NRP-1-wt transfection or not. (**G**) The expression of Wnt3a and β-catenin was examined in cells depicted in (**A**). Data are presented as mean±SD; \*\**P*\<0.01 vs NC or control.\
**Abbreviations:** qRT-PCR, quantitative real-time PCR; mut, mutant; NC, negative control; NRP-1, neuropilin-1; wt, wild-type.](ott-11-5293Fig2){#f2-ott-11-5293}

![miR-376a overexpression inhibits breast cancer cell proliferation and promoted cell apoptosis.\
**Notes:** (**A** and **B**) MDA-MB-453 and MDA-MB-231 cells with miR-376a overexpression or not were subjected to analyze the cell viability by CCK8 assay. (**C** and **D**) Cell apoptosis was detected in cells depicted in (**A**). (**E**) The expression of apoptosis executors (cleaved caspase 3 and cleaved PARP) was examined in cells depicted in (**A**). Data are presented as mean±SD; \**P*\<0.05, \*\**P*\<0.01 vs NC or control.\
**Abbreviations:** FITC, fluorescein isothiocyanate; h, hours; NC, negative control.](ott-11-5293Fig3){#f3-ott-11-5293}

![miR-376a overexpression suppresses breast cancer cells migration, invasion and EMT process.\
**Notes:** (**A**) The migration ability was measured in MDA-MB-453 and MDA-MB-231 cells with miR-376a overexpression or not. (**B**) The invasion ability was determined in cells depicted in (**A**). (**C**) The EMT process was evaluated in cells depicted in (**A**) via detecting the epithelial marker (E-cadherin) and mesenchymal marker (Vimentin) expression by Western blot assay. Data are presented as mean±SD; \*\**P*\<0.01 vs NC or control.\
**Abbreviation:** EMT, epithelial--mesenchymal transition; NC, negative control.](ott-11-5293Fig4){#f4-ott-11-5293}

###### 

Overexpression of NRP-1 or inhibition of Wnt/β-catenin signaling rescues the inhibitory effects of miR-376a on breast cancer cell progression.

**Notes:** (**A** and **B**) The cell viability was examined in MDA-MB-453 and MDA-MB-231 cells with miR-376a overexpression as well as NRP-1 knockdown or SKL2001 treatment. (**C**) Cell migration ability was detected in cells depicted in (**A**). (**D**) The expression of epithelial (E-cadherin) and mesenchymal markers (Vimentin) was measured in cells depicted in (**A**). (**E**) Cell apoptosis was evaluated in cells depicted in (**A**). (**F**) The expression of apoptosis executors (cleaved caspase 3 and cleaved PARP) was determined in cells depicted in (**A**). Data are presented as mean±SD; \**P*\<0.05, \*\**P*\<0.01 vs NC or control.

**Abbreviations:** FITC, fluorescein isothiocyanate; h, hours; NRP-1, neuropilin-1; NC, negative control.
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![Proposed model that miR-376a inhibits breast cancer cell progression.\
**Note:** miR-376a suppressed breast cancer cell proliferation and migration and promotes cell apoptosis via targeting NRP-1 and thus inhibiting Wnt/β-catenin pathway.\
**Abbreviation:** NRP-1, neuropilin-1.](ott-11-5293Fig6){#f6-ott-11-5293}
